Trial Profile
A Pilot, Proof-of-concept, Single-arm, Phase II Study to Assess the Clinical Activity and Tolerability of Oral Rigosertib Administered Continuously in Patients with Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Expressing Mutated Ras
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2014
Price :
$35
*
At a glance
- Drugs Rigosertib (Primary)
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 27 Sep 2014 New trial record